Recorded December 11, 2015
The practical details of making precision medicine possible is the topic of our talk. Mainstream clinical lab software systems are fundamentally clinical chemistry systems. Molecular labs must be able to work with molecular data, which is different -
deeper and more complex. Michael Bolick, CEO and Jeremy Stuart, PhD, VP of Genetic Services, Selah Genomics will present a case study along with members of the UNIConnect team, describing the inspiration for investing in a molecular LIMS, experiences,
lessons learned and points to consider if your organization is in need of technology to support your molecular lab, but not sure of next steps or sound alternatives.
1. Differences between conventional LIS and MDx lab software
2. Laboratory operational benefits to deploying MDx software – TAT, efficiency, quality,
audit success etc.
benefits to deploying MDx software
a. client service
b. managing external sales organizations
d. ability to capture
e. ability to respond to changing Medicare reimbursement policies
Founder, Chairman of the Board, Chief Executive Officer and President
Selah Technologies, LLC
Mr. Michael Bolick is Founder of Selah Technologies, LLC and serves as its Chairman of the Board, Chief Executive Officer and President. Mr. Bolick served as Vice President of Manufacturing Operations for Manufacturing, Inc., a subsidiary of Irix
Pharmaceuticals, Inc. He joined IRIX in 2002 following the acquisition of the IRIX Manufacturing facility in Greenville, South Carolina. Prior to the acquisition, he was responsible for Manufacturing Operations at the Greenville site since the
1997 grass roots startup. His experience includes startup, qualification and operation of cGMP manufacturing facilities. Mr. Bolick is a graduate of North Carolina State University with a BS in Chemical Engineering.
Jeremy Stuart Sc.D,
Co-Founder & Senior Vice President, Scientific Operations
Selah Technologies, LLC
Dr. Jeremy Stuart graduated from the University of Minnesota with a B.S in Genetics & Cell Biology, where he was subsequently awarded a Regents’ scholarship and obtained an MPH in Toxicology. He then went on to earn his doctorate in Genetics
& Complex Diseases at Harvard University, where he was awarded the prestigious Ruth L. Kirschstein Training Grant. He completed his post-doc fellowship at the Harvard School of Public Health, where he studied the effects of adipose tissue
on the growth of tumor cells using three dimensional cell culture models. Jeremy was recruited to join Agencourt Personal Genomics, were he became a core developer of the SOLiD next-generation sequencing technology. After APG was acquired by Applied
Biosystems, Jeremy served as a Senior Project Coordinator, advising commercial, clinical, and product development strategies around next-generation sequencing at leading institutions. Jeremy has published works in a number of leading scientific
journals and holds several patents in the next-generation sequencing space.
Founder, CEO, CTO
Mr. Harten founded UNIConnect in 1997 and is the creator of the UNIFlow process definition language, process tracking database, and UNIFlow quality compliance engine. Earlier he created the GEDCOM format used to exchange computerized genealogical
information, and successfully campaigned globally for its establishment as a worldwide standard.
Harten is recognized in the database community as a world expert on database architectures for extreme computing requirements. He earned an MS degree in Computer Science and BS in Accounting from Brigham Young University, is a Java programming instructor,
a Sun-certified Java developer and has completed post-graduate work in artificial intelligence at the University of Utah